Workpackage 3 – Remission and immune tolerance in atopic diseases

Lead: Prof. Dr. med. Thomas Bieber, Bonn 

Atopic dermatitis is the most common chronic inflammatory skin condition and is considered the initial phase of the so-called atopic march. Among allergic diseases, atopic dermatitis is a paradigmatic condition since a substantial remission rate (ca. 40%) is observed in affected children, before adolescence. It is assumed that this remission is at least partly due to yet-to-be-explored mechanisms leading to immune tolerance towards environmental agents such as allergens. However these mechanisms have not been systematically studied so far. Thus, atopic dermatitis will be used as a model disease to study the – spontaneous or treatment induced - mechanisms leading to remission of a chronic inflammatory allergic reaction. Our planned research will lead to a direct influence on the lives of patients.  

  • WP 3 processes the key issues (along the lines of: "What can be learnt from the natural course of allergic conditions”) of the entire project in a precedent-setting manner.
  • The aim is to clarify mechanisms of the remission phase of atopic dermatitis and to identify predictive biomarkers that are characteristic of patient subgroups.
  • As a result, new bespoke strategies in the prevention and treatment of atopic dermatitis and other allergic conditions can be implemented as stratified medicine.